Neurology Transformed: Precision Therapies, Enhanced Outcomes

Catherine Osei
Department of Pharmacology, University of Ghana, Accra, Ghana

*Corresponding Authors**

Catherine Osei
Department of Pharmacology, University of Ghana, Accra, Ghana
E-mail: c.osei@ug.edu.gh

Received: 01-Jul-2025; **Accepted:** 08-Aug-2025; **Published:** 08-Aug-2025

Introduction

This article provides an insightful overview of Neuromyelitis Optica Spectrum Disorder (NMOSD), tracing its evolving understanding from a distinct entity to a broader spectrum of autoimmune Central Nervous System (CNS) inflammatory conditions. It highlights the latest diagnostic criteria and the significant progress in therapeutic strategies, emphasizing how new targeted immunotherapies have transformed patient outcomes and prognosis. [1].

This paper reviews the landscape of Alzheimer's disease treatments, focusing on both current pharmacological approaches and promising therapies in development. It discusses the challenges in drug discovery for neurodegenerative diseases and the shift towards early intervention and multi-target strategies, including amyloid and tau-directed therapies, along with symptomatic management. [2].

Here's a comprehensive look at the treatment options for Parkinson's disease. The authors delve into established pharmacotherapies like levodopa and dopamine agonists, alongside emerging treatments aimed at symptom management and disease modification. The discussion touches upon gene therapies, cell-based therapies, and new drug targets, offering perspective on the future of Parkinson's care. [3].

This article offers a concise update on the management of acute ischemic stroke. It underscores the critical importance of rapid diagnosis and timely reperfusion therapies, such as thrombolysis and mechanical thrombectomy. The authors also explore advancements in neuroimaging and post-stroke care, pointing towards strategies for optimizing patient outcomes and reducing long-term disability. [4].

This paper explores significant advancements in treating drug-resistant epilepsy, a challenging condition affecting a substantial portion of epilepsy patients. It covers new anti-seizure medications, surgical options, neuromodulation techniques (like Vagus Nerve Stimulation (VNS) and Deep Brain Stimulation (DBS)), and dietary therapies, offering hope for improved seizure control and quality of life for those with refractory epilepsy. [5].

This review focuses on recent breakthroughs in migraine treatment, highlighting the paradigm shift brought by calcitonin gene-related peptide (CGRP) pathway inhibitors. It discusses the efficacy and safety profiles of both acute and preventive CGRP-targeted therapies, alongside other novel pharmacological and non-pharmacological interventions, providing a fresh perspective on managing this debilitating neurological condition. [6].

This article provides an overview of the rapidly evolving landscape of therapies for Amyotrophic Lateral Sclerosis (ALS). It discusses current approved treatments and critically examines various investigational therapies targeting different pathological mechanisms, including genetic, inflammatory, and protein aggregation pathways. The paper emphasizes the urgency for effective treatments to slow disease progression. [7].

This article outlines the significant progress made in treating Multiple Sclerosis (MS), detailing the expansion of disease-modifying therapies (DMTs). It categorizes DMTs by their mechanisms of action and discusses their impact on reducing relapse rates and slowing disability progression. The authors also touch upon individualized treatment strategies and future directions in MS research. [8].

This paper synthesizes the latest understanding in the diagnosis and management of dementia, covering various forms beyond Alzheimer's. It emphasizes the importance of early detection, accurate differential diagnosis, and holistic care approaches. The review also touches upon modifiable risk factors and non-pharmacological interventions, offering a comprehensive view on managing cognitive decline. [9].

This article investigates the critical role of neuroinflammation in the pathogenesis and progression of various neurodegenerative diseases. It discusses how chronic inflammation in the central nervous system contributes to neuronal damage and highlights potential therapeutic targets aimed at modulating inflammatory responses to slow or halt neurodegeneration. [10].

Description

The understanding and treatment of neurological conditions are undergoing a profound transformation. Neuromyelitis Optica Spectrum Disorder (NMOSD), once considered a distinct entity, is now recognized as part of a broader spectrum of autoimmune Central Nervous System (CNS) inflammatory conditions. This evolving understanding, coupled with advanced diagnostic criteria and the emergence of targeted immunotherapies, has dramatically improved patient outcomes and prognosis [1]. Similarly, Multi-

Cite this article: Osei C,(2025) Neurology Transformed: Precision Therapies, *Enhanced Outcomes. jnn* 16: 388. DOI: 10.35248/2332-2594.25.16.388

ple Sclerosis (MS) care has seen significant progress through an expanded repertoire of disease-modifying therapies (DMTs). These therapies, categorized by diverse mechanisms of action, have proven effective in reducing relapse rates and slowing disability progression, allowing for highly individualized treatment strategies and pointing towards exciting future directions in research [8]. Underlying many of these conditions, neuroinflammation plays a critical role. Investigations highlight how chronic inflammation within the CNS contributes significantly to neuronal damage, thus identifying promising therapeutic targets aimed at modulating these inflammatory responses to slow or potentially halt neurodegeneration [10].

Significant strides are also being made in addressing neurodegenerative diseases, which represent some of the most challenging conditions in neurology. Alzheimer's disease treatments are moving beyond traditional approaches, focusing on both current pharmacological options and promising therapies in development. This includes a notable shift towards early intervention, multi-target strategies, and specific amyloid and tau-directed therapies, alongside comprehensive symptomatic management [2]. For Parkinson's disease, clinicians now employ established pharmacotherapies such as levodopa and dopamine agonists, while actively exploring emerging treatments. These newer approaches aim for both symptom management and disease modification, encompassing gene therapies, cell-based therapies, and innovative drug targets, offering a hopeful perspective on the future of Parkinson's care [3].

Continuing the focus on neurodegeneration, the therapeutic landscape for Amyotrophic Lateral Sclerosis (ALS) is rapidly evolving. Current approved treatments are being critically examined alongside various investigational therapies designed to target distinct pathological mechanisms, including genetic factors, inflammatory pathways, and protein aggregation. The ongoing research underscores the pressing urgency to discover effective treatments that can significantly slow disease progression and improve patient quality of life [7]. Concurrently, the diagnosis and management of dementia have advanced considerably, now covering a wider range of forms beyond just Alzheimer's. This includes a strong emphasis on the importance of early detection, accurate differential diagnosis, and the implementation of holistic care approaches. Reviews also highlight the relevance of modifiable risk factors and non-pharmacological interventions in effectively managing cognitive decline [9].

Beyond chronic neurodegenerative and autoimmune conditions, acute and episodic neurological disorders have also seen remarkable progress in their management. Acute ischemic stroke management critically hinges on rapid diagnosis and the timely application of reperfusion therapies, such as thrombolysis and mechanical thrombectomy. Parallel advancements in neuroimaging and post-stroke care are crucial for optimizing patient outcomes and substantially reducing long-term disability [4]. Addressing drug-resistant epilepsy, a condition affecting a significant portion of epilepsy patients, involves exploring diverse and advanced treatment modalities. These include the development of new anti-seizure medications, sophisticated surgical options, various neuromodulation techniques like Vagus Nerve Stimulation (VNS) and Deep Brain Stimulation (DBS), and targeted dietary therapies. These innovations collectively offer renewed hope for improved seizure control and an enhanced quality of life for individuals with refractory epilepsy [5].

Migraine treatment has experienced a notable paradigm shift, largely driven by the development of calcitonin gene-related peptide (CGRP) pathway inhibitors. These therapies have demonstrated impressive efficacy and safety profiles for both acute and preventive management of migraine. This breakthrough, alongside other novel pharmacological and non-pharmacological interventions, provides a fresh and more effective perspective on managing this often debilitating neurological condition [6]. Collectively, the trajectory of neurological care is marked by an increasing embrace of targeted, personalized, and multi-modal strategies, offering unprecedented hope for patients facing these complex and often challenging disorders.

Conclusion

Recent advancements in neurology are rapidly transforming the management of a wide array of neurological disorders, from autoimmune conditions to neurodegenerative diseases and acute events. Breakthroughs include the redefinition of conditions like Neuromyelitis Optica Spectrum Disorder (NMOSD) with the advent of targeted immunotherapies, and significant progress in Multiple Sclerosis (MS) treatment through expanded disease-modifying therapies. Neuroinflammation's critical role in neurodegeneration is being increasingly understood, opening new therapeutic avenues.

In neurodegenerative diseases, Alzheimer's treatment is shifting towards early, multi-target interventions, while Parkinson's care is advancing with emerging gene and cell-based therapies alongside established pharmacotherapies. Amyotrophic Lateral Sclerosis (ALS) research is intensely focused on investigational therapies targeting various pathological mechanisms, and dementia management emphasizes early detection and holistic care beyond Alzheimer's. Acute conditions like ischemic stroke benefit immensely from rapid diagnosis and reperfusion therapies, improving patient outcomes. Drug-resistant epilepsy is being addressed through new medications, surgical options, and neuromodulation techniques. Furthermore, migraine treatment has been revolutionized by calcitonin gene-related peptide (CGRP) pathway inhibitors. This collective progress highlights a profound shift towards more precise, early, and multi-modal therapeutic strategies across neurology, promising enhanced patient prognoses and quality of life.

References

1. Ahmad R, Gupta M, Dhib-Jalbut *SD. Neuromyelitis Optica Spectrum Disorder* (NMOSD): Latest Developments and Treatment Strategies. Brain Sci. 2021;11:987.

2. May RD, Smith JD, White JA. Recent Advances in Alzheimer's *Disease Therapy. J Alzheimers Dis.* 2023;91:1199-1215.

3. Kordower JH, Dauer WA, Brundin P. Current and Emerging Pharmacotherapies for Parkinson's *Disease. Mov Disord.* 2022;37:1300-1316.

4. Nogueira RG, Noser MG, Ortega-Gutierrez S. Acute Ischemic Stroke: *Current Management and Future Directions. Stroke.* 2020;51:268-278.

5. Berkovic SF, Scheffer IE, Jackson GD. Advances in the Treatment of Drug-Resistant *Epilepsy. N Engl J Med.* 2021;384:1906-1916.

6. Goadsby PJ, Tepper SJ, *Dodick DW. New Treatments for Migraine. N Engl J Med.* 2022;387:1987-1996.

Cite this article: Osei C,(2025) Neurology Transformed: Precision Therapies, *Enhanced Outcomes. jnn* 16: 388. DOI: 10.35248/2332-2594.25.16.388

7. van den Berg LH, Benatar ME, Barohn RJ. Emerging Therapies for Amyotrophic Lateral Sclerosis: *A Review. JAMA Neurol.* 2023;80:206-215.

8. Hauser SL, Waubant E, Bar-Or *A. Advances in the Treatment of Multiple Sclerosis. N Engl J Med.* 2022;386:2105-2117.

9. Livingston G, Sadovnick AD, *Passmore P. Recent Advances in the Diagnosis and Management of Dementia. Lancet.* 2020;396:112-125.

10. Bedini M, De Vita MG, *Cavallo AFP. The Role of Neuroinflammation in Neurodegenerative Diseases. Int J Mol Sci.* 2022;23:12061.

Cite this article: Osei C,(2025) Neurology Transformed: Precision Therapies, *Enhanced Outcomes. jnn* 16: 388. DOI: 10.35248/2332-2594.25.16.388